GENT: Record sales, high margins, and robust product growth mark a strong Q1 performance

About this update from Gentian Diagnostics Asa

Record Q1 sales and profitability driven by strong growth across all products and regions, with Cystatin C and other key assays performing exceptionally. Gross margin exceeded 60%, and the NT-proBNP assay is on track for a 2026 commercial launch.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Gentian Diagnostics Asa